The accumulation of cyclin-dependent kinase inhibitor p27(kip1) is a primary response to staurosporine and independent of G1 cell cycle arrest

Experimental Cell Research

Volumn 243, Issue 2, 1998, Pages 222-231

  Nishi, Kayoko ^a   Schnier, Joachim B ^a   Bradbury, E Morton ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27; STAUROSPORINE;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL STRAIN 3T3; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ANIMALIA;

EID: 0032531142     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1998.4166     Document Type: Article

References (66)

1. Crissman H. A., Gadbois D. M., Tobey R. A., Bradbury E. M. Transformed mammalian cells are deficient in kinase-mediated control of progression through the G1 phase of the cell cycle. Proc. Natl. Acad. Sci. USA. 88:1991;7580-7584.
2. Abe K., Yoshida M., Usui T., Horinouchi S., Beppu T. Highly synchronous culture of fibroblasts from G2 block caused by staurosporine, a potent inhibitor of protein kinases. Exp. Cell Res. 192:1991;122-127.
3. Schnier J. B., Gadbois D. M., Nishi K., Bradbury E. M. The kinase inhibitor staurosporine induces G1 arrest at two points: Effect on retinoblastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells. Cancer Res. 54:1994;5959-5963.
4. Akinaga S., Nomura K., Gomi K., Okabe M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother. Pharmacol. 33:1994;273-280.
5. Kwon T. K., Buchholz M. A., Chrest F. J., Nordin A. A. Staurosporine-induced G1 arrest is associated with the induction and accumulation of cyclin-dependent kinase inhibitors. Cell Growth Differ. 7:1996;1305-1313.
6. Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
7. DeCaprio J. A., Ludlow J. W., Figge J., Shew J. Y., Huang C. M., Lee W. H., Marsilio E., Paucha E., Livingston D. M. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell. 54:1988;275-283.
8. Ludlow J. W., DeCaprio J. A., Huang C. M., Lee W. H., Paucha E., Livingston D. M. SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell. 56:1989;57-65.
9. Whyte P., Buchkovich K. J., Horowitz J. M., Friend S. H., Raybuck M., Weinberg R. A., Harlow E. Association between an oncogene and an anti-oncogene: The adenovirus E1A proteins bind to the retinoblastoma gene product. Nature. 334:1988;124-129.
10. Dyson N., Howley P. M., Munger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 243:1989;934-937.
11. Munger K., Werness B. A., Dyson N., Phelps W. C., Harlow E., Howley P. M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8:1989;4099-4105.
12. Schnier J. B., Nishi K., Goodrich D. W., Bradbury E. M. G1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc. Natl. Acad. Sci. USA. 93:1996;5941-5946.
13. DeCaprio J. A., Ludlow J. W., Lynch D., Furukawa Y., Griffin J., Piwnica-Worms H., Huang C. M., Livingston D. M. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell. 58:1989;1085-1095.
14. Buchkovich K., Duffy L. A., Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell. 58:1989;1097-1105.
15. Chen P. L., Scully P., Shew J. Y., Wang J. Y., Lee W. H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell. 58:1989;1193-1198.
16. Akiyama T., Ohuchi T., Sumida S., Matsumoto K., Toyoshima K. Phosphorylation of the retinoblastoma protein by cdk2. Proc. Natl. Acad. Sci. USA. 89:1992;7900-7904.
17. Hinds P. W., Mittnacht S., Dulic V., Arnold A., Reed S. I., Weinberg R. A. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell. 70:1992;993-1006.
18. Morgan D. O. Principles of CDK regulation. Nature. 374:1995;131-134.
19. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
20. El-Deiry W. S., Harper J. W., O'Connor P. M., Velculescu V. E., Canman C. E., Jackman J., Pietenpol J. A., Burrell M., Hill D. E., Wang Y., Wiman K. G., Mercer W. E., Kastan M. B., Kohn K. W., Elledge S. J., Kinzler K. W., Vogelstein B. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
21. Dulic V., Kaufmann W. K., Wilson S. J., Tlsty T.D., Lees E., Harper J. W., Elledge S. J., Reed S. I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 76:1994;1013-1023.
22. Kato J. Y., Matsuoka M., Polyak K., Massague J., Sherr C. J. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell. 79:1994;487-496.
23. Jeoung D. I., Tang B., Sonenberg M. Induction of tumor suppressor p21 protein by kinase inhibitors in MCF-7 cells. Biochem. Biophys. Res. Commun. 214:1995;361-366.
24. Tobey R. A., Oishi N., Crissman H. A. Cell cycle synchronization: Reversible induction of G2 synchrony in cultured rodent and human diploid fibroblasts. Proc. Natl. Acad. Sci. USA. 87:1990;5104-5108.
25. Herrera R. E., Sah V. P., Williams B. O., Makela T. P., Weinberg R. A., Jacks T. Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol. Cell. Biol. 16:1996;2402-2407.
26. Tobey R. A., Crissman H. A. Cell-cycle analysis in 20 minutes. Science. 184:1974;1297-1298.
27. Laemmli U. K. Cleavage of structure proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
28. Hensel C. H., Xiang R. H., Sakaguchi A. Y., Naylor S. L. Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer. Oncogene. 6:1991;1067-1071.
29. Kashii T., Mizushima Y., Monno S., Nakagawa K., Kobayashi M. Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method. J. Cancer Res. Clin. Oncol. 120:1994;143-148.
30. Harbour J. W., Lai S. L., Whang-Peng J., Gazdar A. F., Minna J. D., Kaye F. J. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 241:1988;353-357.
31. D'Amico D., Carbone D., Mitsudomi T., Nau M., Fedorko J., Russell E., Johnson B., Buchhagen D., Bodner S., Phelps R., Gazdar A., Minna J. D. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene. 7:1992;339-346.
32. Runnebaum I. B., Nagarajan M., Bowman M., Soto D., Sukumar S. Mutations in p53 as potential molecular markers for human breast cancer. Proc. Natl. Acad. Sci. USA. 88:1991;10657-10661.
33. Nigro J. M., Baker S. J., Preisinger A. C., Jessup J. M., Hostetter R., Cleary K., Bigner S. H., Davidson N., Baylin S., Devilee P., Glover T., Collins F. S., Weston A., Modali R., Harris C. C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature. 342:1989;705-708.
34. Bartek J., Iggo R., Gannon J., Lane D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene. 5:1990;893-899.
35. T'Ang A., Varley J. M., Chakraborty S., Murphree A. L., Fung Y. K. Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science. 242:1988;263-266.
36. Wang N. P., To H., Lee W. H., Lee E. Y. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene. 8:1993;279-288.
37. Diller L., Kassel J., Nelson C. E., Gryka M. A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S. J., Vogelstein B., Friend S. H. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 10:1990;5772-5781.
38. Li W., Fan J., Hochhauser D., Banerjee D., Zielinski Z., Almasan A., Yin Y., Kelly R., Wahl G. M., Bertino J. R. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc. Natl. Acad. Sci. USA. 92:1995;10436-10440.
39. Cottu P. H., Muzeau F., Estreicher A., Flejou J. F., Iggo R., Thomas G., Hamelin R. Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene. 13:1996;2727-2730.
40. Rodrigues N. R., Rowan A., Smith M. E., Kerr I. B., Bodmer W. F., Gannon J. V., Lane D. P. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA. 87:1990;7555-7559.
41. Lee W. H., Bookstein R., Hong F., Young L. J., Shew J. Y., Lee E. Y. Human retinoblastoma susceptibility gene: Cloning, identification, and sequence. Science. 235:1987;1394-1399.
42. Rieger K. M., Little A. F., Swart J. M., Kastrinakis W. V., Fitzgerald J. M., Hess D. T., Libertino J. A., Summerhayes I. C. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br. J. Cancer. 72:1995;683-690.
43. Horowitz J. M., Yandell D. W., Park S. H., Canning S., Whyte P., Buchkovich K., Harlow E., Weinberg R. A., Dryja T. P. Point mutational inactivation of the retinoblastoma antioncogene. Science. 243:1989;937-940.
44. Van Meir E. G., Kikuchi T., Tada M., Li H., Diserens A. C., Wojcik B. E., Huang H. J., Friedmann T., de Tribolet N., Cavenee W. K. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 54:1994;649-652.
45. Harlow E., Williamson N. M., Ralston R., Helfman D. M., Adams T. E. Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor antigen p53. Mol. Cell. Biol. 5:1985;1601-1610.
46. Fang F., Orend G., Watanabe N., Hunter T., Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science. 271:1996;499-502.
47. Jackson T. R., Blair L. A., Marshall J., Goedert M., Hanley M. R. The mas oncogene encodes an angiotensin receptor. Nature. 335:1988;437-440.
48. Andrawis N. S., Dzau V. J., Pratt R. E. Autocrine stimulation of mas oncogene leads to altered growth control. Cell Biol. Int. Rep. 16:1992;547-556.
49. Yew N., Strobel M., Vande Woude G. F. Mos and the cell cycle: The molecular basis of the transformed phenotype. Curr. Opin. Genet. Dev. 3:1993;19-25.
50. Taylor S. J., Shalloway D. The cell cycle and c-Src. Curr. Opin. Genet. Dev. 3:1996;26-34.
51. Gilman A. G. G proteins: Transducers of receptor-generated signals. Annu. Rev. Biochem. 56:1987;615-649.
52. Bizub D., Blair D., Alvord G., Skalka A. M. Correlation between H-ras p21TLeu61 protein content and tumorigenicity of NIH3T3 cells. Oncogene. 3:1988;443-448.
53. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
54. Kuerbitz S. J., Plunkett B. S., Walsh W. V., Kastan M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA. 89:1992;7491-7495.
55. Lin D., Shields M. T., Ullrich S. J., Appella E., Mercer W. E. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc. Natl. Acad. Sci. USA. 89:1992;9210-9214.
56. Sarnow P., Ho Y. S., Williams J., Levine A. J. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell. 28:1982;387-394.
57. Werness B. A., Levine A. J., Howley P. M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 248:1990;76-79.
58. Smith M. L., Zhan Q., Bae I., Fornace A. J. Jr. Role of retinoblastoma gene product in p53-mediated DNA damage response. Exp. Cell Res. 215:1994;386-389.
59. Hickman E. S., Bates S., Vousden K. H. Perturbation of the p53 response by human papillomavirus type 16 E7. J. Virol. 71:1997;3710-3718.
60. Cordon-Cardo C., Zhang Z. F., Dalbagni G., Drobnjak M., Charytonowicz E., Hu S. X., Xu H. J., Reuter V. E., Benedict W. F. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 57:1997;1217-1221.
61. Dalbagni G., Cordon-Cardo C., Reuter V., Fair W. R. Tumor suppressor gene alterations in bladder carcinoma: Translational correlates to clinical practice. Surg. Oncol. Clin. N. Am. 4:1995;231-240.
62. Lee M. H., Williams B. O., Mulligan G., Mukai S., Bronson R. T., Dyson N., Harlow E., Jacks T. Targeted disruption of p107: Functional overlap between p107 and Rb. Genes Dev. 10:1996;1621-1632.
63. Hengst L., Reed S. I. Translational control of p27Kip1 accumulation during the cell cycle. Science. 271:1996;1861-1864.
64. Millard S. S., Yan J. S., Nguyen H., Pagano M., Kiyokawa H., Koff A. Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest. J. Biol. Chem. 272:1997;7093-7098.
65. Pagano M., Tam S. W., Theodoras A. M., Beer-Romero P., Del Sal G., Chau V., Yew P. R., Draetta G. F., Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
66. Alessandrini A., Chiaur D. S., Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia. 11:1997;342-345.